Form 4: Immunovant's Chief Medical Officer Sells Shares to Cover Tax Obligations

Michael Geffner, Chief Medical Officer of Immunovant, sold 3,261 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 24, 2024, Michael Geffner, the Chief Medical Officer of Immunovant, Inc., sold 3,261 shares of Immunovant's common stock.
• The shares were sold at a price of $28.9 per share.
• This sale was to cover tax withholding obligations associated with the vesting of 6,250 restricted stock units (RSUs) on April 17, 2024, which were part of a grant of 100,000 RSUs from January 17, 2023.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction.
• Following the transaction, Geffner directly owns 141,616 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction to cover tax obligations. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and employees.

Stakeholder Impact

• The sale of shares by a company executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates